Display options
Cite
Baniasadi S, Farzanegan B, Alehashem M. Important drug classes associated with potential drug-drug interactions in critically ill patients: highlights for cardiothoracic intensivists. Ann Intensive Care. 2015;5(1):44doi: 10.1186/s13613-015-0086-4.
Baniasadi, S., Farzanegan, B., & Alehashem, M. (2015). Important drug classes associated with potential drug-drug interactions in critically ill patients: highlights for cardiothoracic intensivists. Annals of intensive care, 5(1), 44. https://doi.org/10.1186/s13613-015-0086-4
Baniasadi, Shadi, et al. "Important drug classes associated with potential drug-drug interactions in critically ill patients: highlights for cardiothoracic intensivists." Annals of intensive care vol. 5,1 (2015): 44. doi: https://doi.org/10.1186/s13613-015-0086-4
Baniasadi S, Farzanegan B, Alehashem M. Important drug classes associated with potential drug-drug interactions in critically ill patients: highlights for cardiothoracic intensivists. Ann Intensive Care. 2015 Dec;5(1):44. doi: 10.1186/s13613-015-0086-4. Epub 2015 Nov 24. PMID: 26603290; PMCID: PMC4658340.
Copy Download .nbib Format: NLM
Share it on

Ann Intensive Care. 2015 Dec;5(1):44. doi: 10.1186/s13613-015-0086-4. Epub 2015 Nov 24.

Important drug classes associated with potential drug-drug interactions in critically ill patients: highlights for cardiothoracic intensivists.

Annals of intensive care

Shadi Baniasadi, Behrooz Farzanegan, Maryam Alehashem

Affiliations

  1. Virology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran. [email protected].
  2. Tracheal Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran. [email protected].
  3. Tracheal Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran. [email protected].

PMID: 26603290 PMCID: PMC4658340 DOI: 10.1186/s13613-015-0086-4

Abstract

BACKGROUND: Patients in the intensive care unit (ICU) are more prone to drug-drug interactions (DDIs). The software and charts that indicate all interactions may not be proper for clinical usage. This study aimed to identify the main drug classes associated with clinically significant DDIs in cardiothoracic ICU and categorize DDIs to make cardiothoracic intensivists aware of safe medication usage.

METHODS: This prospective study was conducted over 6 months in a cardiothoracic ICU of a university-affiliated teaching hospital. The presence of potential drug-drug interactions (pDDIs) was assessed by a clinical pharmacologist using Lexi-Interact database. Clinically significant pDDIs were defined according to severity and reliability rating. Interacting drug classes, mechanisms, and recommendations were identified for each interaction.

RESULTS: From 1780 administered drugs, 496 lead to major (D) and contraindicated (X) interactions. Nine drug classes were responsible for D and/or X interactions with excellent (E) and/or good (G) reliability. Anti-infective agents (45.87 %) were the main drug classes that caused clinically significant pDDIs followed by central nervous system drugs (14.67 %). Azole antifungals as the most interacting antimicrobial agents precipitated metabolism inhibition of CYP3A substrates.

CONCLUSIONS: Clinically significant pDDIs as potential patient safety risks were prevalent in critically ill patients. The findings from current study help to improve knowledge and awareness of clinicians in this area and minimize adverse events due to pDDIs.

References

  1. Crit Care Clin. 2006 Apr;22(2):273-90, vi - PubMed
  2. Pharm Pract (Granada). 2007 Oct;5(4):157-61 - PubMed
  3. Am J Manag Care. 2007 Oct;13(10):573-8 - PubMed
  4. Curr Clin Pharmacol. 2013 Feb 1;8(1):25-38 - PubMed
  5. Curr Opin Crit Care. 2007 Dec;13(6):725-31 - PubMed
  6. Saudi Med J. 2005 Apr;26(4):548-52 - PubMed
  7. Fundam Clin Pharmacol. 2008 Oct;22(5):493-501 - PubMed
  8. Drug Metab Dispos. 2010 Sep;38(9):1499-504 - PubMed
  9. Acta Anaesthesiol Scand. 2015 May;59(5):576-85 - PubMed
  10. Dermatol Ther. 2014 Jan-Feb;27(1):1-11 - PubMed
  11. Curr Opin Nephrol Hypertens. 2009 Sep;18(5):404-11 - PubMed
  12. J Neurosci Rural Pract. 2011 Jul;2(2):119-23 - PubMed
  13. Acta Anaesthesiol Scand. 2013 Aug;57(7):835-47 - PubMed
  14. Drug Saf. 1997 Apr;16(4):267-78 - PubMed
  15. Basic Clin Pharmacol Toxicol. 2008 Apr;102(4):408-11 - PubMed
  16. Pharmacoepidemiol Drug Saf. 2013 Apr;22(4):430-7 - PubMed
  17. Int J Clin Pharm. 2013 Jun;35(3):455-62 - PubMed
  18. Dermatol Clin. 2009 Jan;27(1):91-4 - PubMed
  19. Drug Saf. 2010 Oct 1;33(10):879-88 - PubMed
  20. J Clin Pharm Ther. 2002 Oct;27(5):377-82 - PubMed
  21. Pharmacotherapy. 2014 Mar;34(3):213-9 - PubMed
  22. Clin Pharmacol Ther. 1977 Sep;22(3):322-8 - PubMed
  23. Rev Lat Am Enfermagem. 2009 Mar-Apr;17(2):222-7 - PubMed
  24. Anesthesiology. 2000 Mar;92(3):821-32 - PubMed
  25. Expert Opin Drug Saf. 2010 Sep;9(5):699-712 - PubMed
  26. J Infect Dev Ctries. 2014 Oct 15;8(10):1267-71 - PubMed
  27. Rev Bras Ter Intensiva. 2008 Dec;20(4):349-54 - PubMed
  28. J Antimicrob Chemother. 2003 Feb;51(2):453-7 - PubMed
  29. Crit Care. 2005 Feb;9(1):45-50 - PubMed
  30. Crit Care. 2012 Dec 12;16(2):218 - PubMed
  31. Pharm World Sci. 2007 Apr;29(2):51-7 - PubMed
  32. Clinics (Sao Paulo). 2011;66(1):9-15 - PubMed
  33. Crit Care Med. 2002 Jan;30(1):142-56 - PubMed
  34. Int J Pharm Pract. 2012 Dec;20(6):402-8 - PubMed
  35. Ther Clin Risk Manag. 2013;9:215-21 - PubMed

Publication Types